UCB SA (OTCMKTS:UCBJY) Stock Short Interest Falls 63.8%

UCB SA (OTCMKTS:UCBJY – Get Free Report) was the recipient of a large drop in short interest during the month of October. As of October 30th, there was short interest totaling 7,614 shares, a drop of 63.8% from the October 15th total of 21,017 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 76,592 shares, the days-to-cover ratio is currently 0.1 days.

UCB Stock Performance

Shares of UCBJY stock opened at $163.75 on Monday. UCB has a 1 year low of $110.55 and a 1 year high of $168.76. The stock’s 50 day simple moving average is $131.08 and its two-hundred day simple moving average is $140.66.

Analysts Set New Price Targets

Several research firms recently weighed in on UCBJY. Zacks Research upgraded shares of UCB from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 27th. Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a research report on Monday, August 3rd. Two research analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy”.

View Our Latest Research Report on UCB

About UCB

(Get Free Report)

UCB is a Belgian biopharmaceutical company headquartered in Brussels. Founded in 1928, it develops medicines for people with serious neurological and immune-mediated diseases, with research focused on areas such as epilepsy and inflammatory conditions. Its products include epilepsy treatments such as Briviact and Vimpat, as well as medicines for immune-mediated diseases, including Bimzelx and Cimzia. Product availability and approved uses vary by country. UCB serves patients and healthcare providers across international markets through its global operations.

Further Reading

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.